rosiglitazone has been researched along with Vasculitis in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gou, W; Ji, Y; Liu, J; Liu, N; Wang, Z | 1 |
| Cantürk, Z; Cetinarslan, B; Komsuoglu, B; Sahin, T; Tarkun, I; Türemen, E | 1 |
| Balletshofer, B; Häring, HU; Hetzel, J; Hombach, V; Koenig, W; Kratzer, W; Marx, N; Rittig, K; Walcher, D | 1 |
| Allen, TJ; Calkin, AC; Cooper, ME; Forbes, JM; Jandeleit-Dahm, KA; Lassila, M; Smith, CM | 1 |
| Parson, H; Ullal, J; Vinik, A | 1 |
| Kapiotis, S; Krzyzanowska, K; Mittermayer, F; Pleiner, J; Roden, M; Schaller, G; Wolzt, M | 1 |
| Al-Massarani, G; Andriantsitohaina, R; Martínez, MC; Reitenbach, S; Tesse, A; Wangensteen, R | 1 |
| Chin-Dusting, J; Cooper, ME; Jandeleit-Dahm, KA; Kling, D; Mizrahi, J; Murphy, A; Sebokova, E; Sheehy, K; Tikellis, C; Woollard, KJ | 1 |
1 review(s) available for rosiglitazone and Vasculitis
| Article | Year |
|---|---|
The role of PPARs in the microvascular dysfunction in diabetes.
Topics: Animals; Diabetes Mellitus, Type 2; Fatty Acids; Humans; Hypoglycemic Agents; Insulin Resistance; Microcirculation; Nitric Oxide; Peroxisome Proliferator-Activated Receptors; Pioglitazone; Rosiglitazone; Skin; Thiazolidinediones; Vasculitis | 2006 |
3 trial(s) available for rosiglitazone and Vasculitis
| Article | Year |
|---|---|
Effect of rosiglitazone on insulin resistance, C-reactive protein and endothelial function in non-obese young women with polycystic ovary syndrome.
Topics: Adult; Biomarkers; Body Weight; C-Reactive Protein; Endothelium, Vascular; Female; Hormones; Humans; Hypoglycemic Agents; Insulin Resistance; Muscle, Smooth, Vascular; Obesity; Polycystic Ovary Syndrome; Rosiglitazone; Thiazolidinediones; Vasculitis | 2005 |
Rapid effects of rosiglitazone treatment on endothelial function and inflammatory biomarkers.
Topics: Adult; Atherosclerosis; Biomarkers; C-Reactive Protein; E-Selectin; Endothelium, Vascular; Humans; Hypoglycemic Agents; Male; Rosiglitazone; Serum Amyloid A Protein; Thiazolidinediones; Vasculitis; Vasodilation | 2005 |
Rosiglitazone prevents free fatty acid-induced vascular endothelial dysfunction.
Topics: Acetylcholine; Adult; Anticoagulants; Arginine; C-Reactive Protein; Endothelium, Vascular; Fatty Acids, Nonesterified; Forearm; Heparin; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Methylation; Nitroglycerin; Plethysmography; Regional Blood Flow; Rosiglitazone; Thiazolidinediones; Vasculitis; Vasodilation; Vasodilator Agents | 2007 |
4 other study(ies) available for rosiglitazone and Vasculitis
| Article | Year |
|---|---|
PPARgamma agonist, rosiglitazone, regulates angiotensin II-induced vascular inflammation through the TLR4-dependent signaling pathway.
Topics: Angiotensin II; Animals; Aorta, Thoracic; Blood Pressure; Cell Survival; Cells, Cultured; Disease Models, Animal; Gene Expression; Gene Silencing; Hypoglycemic Agents; Male; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; PPAR gamma; Rats; Rats, Sprague-Dawley; RNA Interference; RNA, Small Interfering; Rosiglitazone; Signal Transduction; Thiazolidinediones; Toll-Like Receptor 4; Vasculitis | 2009 |
Rosiglitazone attenuates atherosclerosis in a model of insulin insufficiency independent of its metabolic effects.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Blood Glucose; Cholesterol; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Disease Models, Animal; Glycated Hemoglobin; Hypoglycemic Agents; Insulin; Male; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Oxidative Stress; Rosiglitazone; Thiazolidinediones; Triglycerides; Vasculitis | 2005 |
Rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, prevents microparticle-induced vascular hyporeactivity through the regulation of proinflammatory proteins.
Topics: Animals; Aorta; Cell Membrane; Cells, Cultured; Cytoplasmic Vesicles; Endothelium, Vascular; Humans; Male; Membrane Proteins; Mice; PPAR gamma; Rosiglitazone; Thiazolidinediones; Vasculitis | 2008 |
Reduced plaque formation induced by rosiglitazone in an STZ-diabetes mouse model of atherosclerosis is associated with downregulation of adhesion molecules.
Topics: Animals; Aortic Diseases; Apolipoproteins E; Atherosclerosis; Cell Adhesion Molecules; Cells, Cultured; Chemokine CCL2; Diabetes Mellitus, Experimental; Diabetic Angiopathies; Disease Models, Animal; Down-Regulation; Endothelial Cells; Humans; Hypoglycemic Agents; Intercellular Adhesion Molecule-1; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; P-Selectin; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Umbilical Veins; Vascular Cell Adhesion Molecule-1; Vasculitis | 2008 |